Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer | Zendy

George Douganiotis | Zendy; Loukas Kontovinis | Zendy; Efrosini Markopoulou | Zendy; Alexandra Ainali | Zendy; Thomas Zarampoukas | Zendy; Ioannis Natsiopoulos | Zendy; Konstantinos Papazisis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer

Author(s) -

George Douganiotis,

Loukas Kontovinis,

Efrosini Markopoulou,

Alexandra Ainali,

Thomas Zarampoukas,

Ioannis Natsiopoulos,

Konstantinos Papazisis

Publication year - 2022

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10111

Subject(s) - breast cancer , medicine , immunohistochemistry , oncology , hormonal therapy , trastuzumab , hormone receptor , cancer , progesterone receptor , population , hormone therapy , lobular carcinoma , pathology , ductal carcinoma , estrogen receptor , environmental health

A possible role of antibody-drug conjugates against tumors with low HER2-expression, leads to the emergence of a new "low-HER2" classification in breast cancer, encompassing tumors from the hormonal-receptor-positive and the triple-negative subgroups. There is a need for data (clinical trial data and real-world evidence) that will accurately describe this population, the risk of recurrence and the possible benefit of HER2 targeted therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research